DAIDS (Division of AIDS) News Releases

Novel Intervention Halves Rate of Death Among People Living with HIV Who Inject Drugs
August 30, 2018

An intervention designed to facilitate treatment for HIV and substance use was associated with a 50 percent reduction in mortality for people living with HIV who inject illicit drugs, a study has found. In addition, the people who received the intervention were nearly twice as likely to report being in treatment for HIV and substance use after one year as those who received their national standard of care. They also were about twice as likely to have suppressed their HIV to undetectable levels after one year.

NIH Officials: Closing Treatment Gaps Critical to Ending the U.S. HIV Epidemic
August 20, 2018

Daily antiretroviral therapy (ART) that suppresses HIV to levels undetectable by standard blood tests is lifesaving for individuals living with HIV and prevents sexual transmission of the virus to others. The public health community must use targeted interventions, however, to do a better job of reaching populations with low levels of viral suppression, according to experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

Fauci: HIV Remission Free of Antiretroviral Therapy Is a Feasible Goal
July 25, 2018

Long-lasting control of HIV infection without antiretroviral therapy (ART) is a feasible goal that deserves vigorous pursuit, Anthony S. Fauci, M.D., will assert during a lecture on Wednesday, July 25 at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam. Dr. Fauci directs the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. His lecture is titled, “Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Challenges.”

Multi-Disease Health Fairs, Universal "Test and Treat" Help East African Communities Achieve HIV Benchmarks
July 25, 2018

People living with HIV in rural East African communities that hosted annual community health campaigns initiated antiretroviral therapy (ART) earlier and had higher levels of overall survival and viral suppression than communities receiving standard HIV care, according to study data presented today at a press conference at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam.

High Uptake and Use of Vaginal Ring for HIV Prevention Observed in Open-Label Study
March 6, 2018

Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to an interim analysis of study data. In addition, the rate of HIV infection among participants in the open-label study, which has no placebo arm for comparison, is half of what might be expected in the absence of the ring, according to mathematical modeling that has significant limitations. 

One-Month Tuberculosis Prophylaxis as Effective as Nine-Month Regimen for People Living with HIV
March 5, 2018

A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. Adults and adolescents in the trial were more likely to complete the short-course regimen—consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid.

NIH Begins Large HIV Treatment Study in Pregnant Women
January 24, 2018

The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants. The study will evaluate the current preferred first-line regimen for pregnant women recommended by the World Health Organization (WHO) and two regimens containing newer antiretroviral drugs that are becoming more widely used.

Study Links Gut-Homing Protein Levels with HIV Infection Risk, Disease Progression
January 24, 2018

For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV. 

NIH Statement on World AIDS Day 2017
December 1, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesMaureen M. Goodenow, Ph.D., Director, Office of AIDS Research

NIH and Partners Launch HIV Vaccine Efficacy Study
November 30, 2017

The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection. The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent occurred in eastern and southern Africa, with women and girls disproportionately affected.

NIH Launches HIV Prevention Trial of Long-Acting Injectable Medication in Sexually Active Women
November 30, 2017

The first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women has begun. The study in southern and eastern Africa will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every eight weeks can safely protect women at risk for HIV infection. The only drug regimen currently licensed for HIV pre-exposure prophylaxis, or PrEP, is the anti-HIV medication Truvada taken daily as an oral tablet. The U.S.

Combination HIV Prevention Reduces New Infections by 42 Percent in Ugandan District
November 29, 2017

A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.

Investigators found that HIV incidence dropped by 42 percent among nearly 18,000 people in Rakai District, Uganda, during a seven-year period in which the rates of HIV treatment and voluntary medical male circumcision increased significantly.

In Adolescents, Oral Truvada and Vaginal Ring for HIV Prevention Are Safe, Acceptable
July 25, 2017

A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, two teams of investigators reported today at the 9th IAS Conference on HIV Science in Paris. The experimental ring is designed for HIV prevention and the oral tablet is already used for this purpose in adults. Adherence to the ring was high, while adherence to the tablet was moderate and diminished substantially when study visits became less frequent.

Drug Interaction Concerns May Negatively Affect HIV Treatment Adherence Among Transgender Women
July 24, 2017

Transgender women—people whose birth certificates indicate or once indicated male sex but who identify as women—are at high risk of HIV acquisition, and thus are a key population for HIV prevention and treatment efforts.

Child Living with HIV Maintains Remission Without Drugs Since 2008
July 24, 2017

A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. This case appears to be the third reported instance of sustained HIV remission in a child after early, limited anti-HIV treatment. 

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses
July 24, 2017

Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate vaccine safety and efficacy among women at risk of acquiring HIV.

NIH Statement on HIV Vaccine Awareness Day 2017
May 18, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID

NIH Statement on World Tuberculosis Day
March 24, 2017

Statement of Christine F. Sizemore, PhD., Richard Hafner, M.D., and Anthony S. Fauci, M.D. National Institute of Allergy and Infectious DiseasesNational Institutes of Health

Monkeys Suppress HIV-Like Virus for Extended Period after Dual-Antibody Treatment
March 13, 2017

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.  

NIH Launches First Large Trial of a Long-Acting Injectable Drug for HIV Prevention
December 20, 2016

The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet.

NIH Statement on World AIDS Day 2016
December 1, 2016

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID

First New HIV Vaccine Efficacy Study in Seven Years Has Begun
November 27, 2016

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day. 

Antibody VRC01 Safe, Only Modest Effect in Controlling HIV Without Antiretroviral Therapy
November 9, 2016

Infusions of an anti-HIV antibody known as VRC01 were shown to be safe and maintained intended antibody concentrations in the blood of people living with HIV, according to two related studies by scientists at the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG). The antibody modestly suppressed blood levels of HIV in people who stopped taking antiretroviral therapy (ART), but the delay in the reappearance of virus was not clinically significant.

Large Increases in HIV Suppression Needed to Reduce New Infections in Critical Population
October 19, 2016

Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on data from Baltimore. Access and adherence to antiretroviral therapy are key to sustained HIV suppression, which dramatically reduces the risk of transmitting HIV to others.

Women Report Vaginal Ring for Preventing HIV Had Little Effect on Sexual Intercourse
October 18, 2016

Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear. This finding is among several insights gleaned about experiences of women who used the ring during the ASPIRE study, also known as MTN-020, announced today at the HIV Research for Prevention (HIVR4P) meeting in Chicago.

Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
October 13, 2016

Scientists at the National Institutes of Health (NIH) and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys. The animals’ immune systems have been suppressing the virus to undetectable levels for as long as 23 months since the monkeys completed an investigational treatment regimen. In addition, the regimen has led to the near-complete replenishment of key immune cells that SIV had destroyed, something unachievable with antiretroviral therapy (ART) alone. The findings will be published in the Oct.

NIH-Funded Scientists Identify Immunological Profiles of People Who Make Powerful HIV Antibodies
July 29, 2016

People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report. While bNAbs cannot completely clear HIV infections in people who have already acquired the virus, many scientists believe a successful preventive HIV vaccine must induce bNAbs

Vaginal Ring May Cut HIV Infection Risk if Used Consistently
July 18, 2016

A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent. This finding is being reported today at a press briefing at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, and will be presented in more detail tomorrow in a lecture at the conference.

NIH Expands Investment in HIV Cure Research
July 13, 2016

The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research.

Large-Scale HIV Vaccine Trial to Launch in South Africa
May 18, 2016

An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.

AIDS-Kaposi’s Sarcoma Study Ended
May 5, 2016

Enrollment into a clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) investigating two different strategies to treat limited-stage AIDS-related Kaposi’s sarcoma was stopped due to futility—if continued, the study would be unlikely to detect a difference between the two study arms.

Animal Study Paints Picture of the Earliest Immune Responses to HIV
April 13, 2016

New research in monkeys exposed to SIV, the monkey equivalent of HIV, suggests that the virus spreads rapidly in the body and triggers early host responses that suppress antiviral immunity, thus promoting viral replication. The study, published in Cell, provides a detailed view of the period between initial mucosal exposure to the virus and the point at which it becomes detectable in the blood.

NIH Launches Large Clinical Trials of Antibody-Based HIV Prevention
April 7, 2016

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the AMP Studies, for antibody-mediated prevention, the trials will test whether giving people an investigational anti-HIV antibody called VRC01 as an intravenous infusion every 8 weeks is safe, tolerable and effective at preventing HIV infection.

AIDS-Kaposi’s Sarcoma Study Changed Due to Drug Underperformance
March 18, 2016

A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) comparing three advanced Kaposi’s sarcoma chemotherapy regimens in combination with antiretroviral treatment (ART) for patients with AIDS will no longer enroll participants in the study arm testing the oral chemotherapy drug etoposide.

Maraviroc-Containing Regimens Safe, Tolerable When Taken for HIV Prevention
February 24, 2016

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.

NIH-Funded Study Finds Critical Population Adheres to PrEP with Coordinated Care
February 24, 2016

New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals.

NIH-Funded Study Finds Effect of PrEP on Bone Density is Reversible
February 23, 2016

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial
February 22, 2016

A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found.

Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
January 27, 2016

In HIV-infected patients undergoing antiretroviral therapy (ART), ongoing HIV replication in lymphoid tissues such as the lymph nodes helps maintain stores, or reservoirs, of the virus, a new study funded by the National Institutes of Health suggests.

HIV Antibody Infusion Safely Suppresses Virus in Infected People
December 23, 2015

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report. 

NIH Statement on World AIDS Day 2015
November 30, 2015

​When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention. 

NIH Publishes Criteria for Research on Organ Transplantation Between People with HIV Infection
November 25, 2015

The U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection. 

Immune Responses Provide Clues for HIV Vaccine Development
October 21, 2015

Recent research has yielded new information about immune responses associated with—and potentially responsible for—protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. 

Two Paths Pave Way for Development of a Preventive HIV Vaccine
July 23, 2015

National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.

HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
July 20, 2015

​Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report. ​

Cholesterol Metabolism in Immune Cells Linked to HIV Progression
July 17, 2015

Lower levels of cholesterol in certain immune cells-a result of enhanced cholesterol metabolism within those cells-may help explain why some HIV-infected people are able to naturally control disease progression..

NIAID-Funded HIV Vaccine Research Generates Key Antibodies in Animal Models
June 18, 2015

​A trio of studies describes advances toward the development of an HIV vaccine. The study teams demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.

NIH-Supported Clinical Trials to Evaluate Long-Acting, Injectable Antiretroviral Drugs to Prevent HIV Infection
February 18, 2015

​Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases and conducted by the NIAID-funded HIV Prevention Trials Network.

NIH-Sponsored HIV Vaccine Trial Launches in South Africa
February 18, 2015

​A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants.

NIH-Funded Scientists Create Potential Long-Acting HIV Therapeutic
February 18, 2015

​Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies. 

NIH Statement on World AIDS Day 2014
December 1, 2014
​Remarkable progress has been made in the fight against HIV/AIDS since the first annual World AIDS Day was commemorated 26 years ago. Yet, we are still far from achieving our goal of a world without AIDS.  
Starting Treatment Soon After HIV Infection Improves Immune Health, Study Finds
November 24, 2014

A study by National Institutes of Health grantees suggests that the best time to start treatment for HIV infection also should be based on how much time has elapsed since becoming HIV-infected.

NIH-Sponsored Study Identifies Superior Drug Regimen for Preventing Mother-to-Child HIV Transmission
November 17, 2014

​For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.

NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns
November 3, 2014

A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period.

Model by NIH Grantees Explains Why HIV Prevention Dosing Differs by Sex
October 30, 2014

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

BULLETIN: In South Africa, RV144 HIV Vaccine Regimen Induces Immune Responses Similar to Those Seen in Thailand
October 28, 2014

​The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa. The results from the trial, called HVTN 097, bode well for plans to test a similar experimental vaccine regimen in South Africa beginning in 2015 in an effort to build upon the results of the RV144 study.

NIH-Led Study Explores Prevention of Heart Disease in HIV-Infected People
October 28, 2014

​The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy (ART) as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population. The study is funded by NIH's National Institute of Allergy and Infectious Diseases (NIAID).

"Mississippi Baby" Now Has Detectable HIV, Researchers Find
July 10, 2014
The child known as the “Mississippi baby”—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case.   
BULLETIN: NIH Expands Focus of Research Funding Opportunity Targeting HIV Reservoirs
February 25, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health, both part of the National Institutes of Health, recently expanded the scientific scope of an HIV-cure related funding announcement to allow for a broader range of studies and approaches.